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Spinal muscular atrophy (SMA), a disease character-
ized by the degeneration of the anterior horn cells of the
spinal cord, causes symmetric proximal muscle weakness.
Inapproximately 95% of cases, SMA is caused by the homo-
zygous deletion of the survival motor neuron 1 (SMN1)
gene (5q13) or its conversion to SMN2 [1]. The prevalence
of SMA, an autosomal recessive disease, is approximately
1 in 10,000 newborns [2]. Hendrickson et al. [3] reported
that the carrier frequency of SMN mutation was different
amongdifferent ethnic groups in North America: the car-
rier frequency was 2.7% in Caucasians, 1.8% in Asians,
1.1% in African Americans, and 0.8% in Hispanics. The
carrier frequency of the later 2 groups was lower than
that of the former groups. Copy number analysis of the
SMN1 gene is important to identify carriers with SMNmu-
tation. The American College of Medical Genetics (ACMG)
recommends universal screening for the presence of SMA
mutation to identify carriers because this condition is as-
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Determination of the copy number of the survival motor neuron (SMN ) gene is important for detect-
ing spinal muscular atrophy (SMA) carriers and compound heterozygous patients. Multiplex ligation-
dependent probe amplification (MLPA) assay is a simple and efficient technique used for detecting
variations in the copy numbers of different genes. Race- and ethnicity-based variation in the SMA
carrier frequency and the ‘2+0’ genotype of SMN1 are important factors that should be considered
when estimating the risk of being an SMA carrier. Since SMN2 plays a disease-modifying role, accu-
rate determination of SMN2 copy numbers in SMA patients can serve as a useful prognostic tool.
Therefore, information on the SMN2 genotype distributions in normal populations will be helpful in
selecting appropriate reference samples for MLPA analysis. To determine SMA carrier frequencies
and SMN genotype distribution, we determined the copy numbers of SMN1 and SMN2 genes using
the MLPA assay in 100 unrelated Korean individuals with no family history of SMA. The frequency
of SMA carriers in the Korean population appears to be 1 in 50, which indicates that the prevalence
of SMA among Koreans is the same as that among individuals in the Western countries. Two of the
100 normal individuals enrolled in this study showed 3 copies of the SMN1 gene. Therefore, 1.0%
of the 198 normal alleles in this population was estimated to be 2-copy alleles (‘2+0’ genotype). SMN2
copy numbers showed a high degree of individual variation. Our results showed that 64% of the indi-
viduals had 2 copies of SMN2, but 36% individuals had between 0, 1, or 3 copies of the gene. (Kore-
an J Lab Med 2010;30:93-6)
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sociated with clinically severe presentation and a high
carrier frequency [4]. Since SMA occurs in all populations,
regardless of race or ethnicity, carrier testing should be
recommended to all couples considering pregnancy or in
early stages of pregnancy. However, carrier testing for
SMA, using SMN1 gene analysis, has not been consid-
ered as a part of routine clinical investigation in such
couples in Korea.
SMN1gene produces full-length transcripts only where-
as the majority of SMN2 transcripts lack exon 7 due to
alternative splicing. In normal subjects, most of the func-
tional SMN protein is a result of the SMN1gene, with only
a very small amount coming from the SMN2gene. In more
than 95% of patients, SMA is due to the deletion of SMN1
or its conversion into SMN2, while in about 5% of the
patients, the disease is caused by intragenic point muta-
tions of SMN1. SMN2 has been reported to play a disease-
modifying role because the SMN2 copy numbers inverse-
ly correlate with the severity of the SMA phenotype. Var-
ious methods have been reported for determining the copy
numbers of the SMN gene; these methods include dena-
tured high-performance liquid chromatography (DHPLC)
and real-time quantitative polymerase chain reaction (PCR)
[5-8]. Real-time PCR is difficult to set up because the mul-
tiplexing required to evaluate a useful number of loci can
be difficult to optimize. DHPLC has been successfully used
in screening for SMA carriers; however, when performed
by inexperienced technicians, this technique yields incon-
sistent results. The multiplex ligation-dependent probe
amplification (MLPA) assay is efficient in the detection of
copy number changes in various genes [3]. Reports indi-
cate that the MLPA assay is better and more efficient
than the 2-step DHPLC. The MLPA assay provides the
unique ability to hybridize several probes specific for SMN1
and SMN2genes in a single experiment [9].
Although SMA is considered to be a panethnic disease,
the epidemiologic data for a specific ethnic group should
be collected since the frequency of the carriers can signifi-
cantly differ among various ethnic groups [3, 10]. We as-
sessed the copy numbers of SMN1 and SMN2genes among
Koreans using the MLPA assay to estimate the SMA car-
rier frequencies and to determine SMN genotype distri-
butions that are required for genetic risk assessment.
We collected blood samples from 100 unrelated Korean
individuals who had no family history of SMA after written
informed consent was obtained from each subject. MLPA
analysis was performed using kits P021 according to the
recommendations of the manufacturer (MRC Holland, Am-
sterdam, Netherlands). The PCR products were analyzed
by using a 310 ABI sequencer (Applied Biosystems, Foster
City, CA, USA). Analysis was performed using the Gene-
Marker software, version 1.6 (Softgenetics, State College,
PA, USA).
The results were classified according to the copy num-
bers of SMN1 and SMN2 (Table 1). The frequency of SMA
carriers (2.0%) determined in this study is similar to that
observed in previous studies conducted in Western coun-
tries and Korea [3, 5, 10]. The copy number of SMN1 can
vary on a chromosome. Two of the 100 individuals inves-
tigated in this study showed 3 copies of the SMN1‘2+1’
genotype (Fig. 1). Therefore, 198 were normal alleles (in-
cluding 2 normal alleles in the individuals with 1 copy of
SMN1, 192 normal alleles in the individuals with 2 copies
of SMN1, and 4 normal alleles in individuals with 3 copies
of SMN1 (the assuming 2+1 genotype)); this shows that
1% of the alleles of these 198 normal alleles were of the
‘2+0’genotype.
Thus, a carrier may possess 2 copies of the gene on 1
chromosome and have 0 copies on another chromosome,
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*Hybrid SMN genes, SMN1 exon 7:SMN2 exon 7/SMN1 exon 8:SMN2
exon 8.
Abbreviations: SMN, survival motor neuron; SMA, spinal muscular atro-
phy.
SMN1:SMN2 ratio No. of subjects Interpretation
1:1 1 SMA carrier
1:3 1 SMA carrier
2:0 2 Noncarrier
2:1 28 Noncarrier
2:2 63 Noncarrier
2:3 3 Noncarrier
3:2 1 Noncarrier
2:2/3:1* 1 Noncarrier
Total 100
Table 1. SMN1 and SMN2 copy numbers in a Korean population
which can lead to a false-negative result when testing for
SMA carrier [11]. In this light, the 2+0 genotype is an essen-
tial factor that needs to be considered when calculating
the risk of being an SMA carrier, the carrier frequency,
and the rates of de novomutation. Therefore, the estima-
tion of the frequency of the 3-copySMN1genotype in the
Korean population is essential for a more reliable assess-
ment of genetic risk. Lee et al. [5] have reported that in a
Korean population, the frequency for 3-copy SMN1 geno-
type, calculated using real-time PCR, was approximate-
ly 19%. Huang et al. [12] conducted a study on a Taiwanese
population using MLPA and reported the frequency of 3-
copy SMN1 to be 7.1%. Our study, which used the same
assay, yielded similar results in Korean population (P
value=0.08).
We also assessed the SMN2 copy numbers in this study
population, and observed a high degree of individual vari-
ation. Sixty-four percent of the individuals had 2 copies
of SMN2, but 36% had 0, 1, or 3 copies of this gene. Since
a higher copy number of the SMN2 has an inverse rela-
tion with the severity of SMA [2], the accurate identifica-
tion of SMN2 copy numbers can serve as a useful tool in
predicting the prognosis of patients with SMA. Although
the SMN2gene number assay would be helpful in a clini-
cal setting, the performance standard for this assay has
not yet been established. The most important shortcom-
ing of the SMN2assay is the lack of adequate controls for
its validation. To determine whether there are any varia-
tions in SMN2 copy numbers, MLPA peak profiles of pati-
ents should be compared with those of reference samples
with normal copy numbers. For example, if we compare
the MLPA peak pattern of an SMA patient with 2 copies
of SMN2 with that of the reference sample with 1 copy of
SMN2, the SMN2 copy number in the patient will show a
false-positive increase. Thus, our results of the SMN2
genotype distributions will facilitate accurate selection of
reference samples with 2 copies of SMN2 in the Korean
population.
In summary, race- and ethnicity-based variation in the
carrier frequency and the ‘2+0’genotype are important
factors that should be considered when estimating the risk
of being an SMA carrier. In addition, de novo mutation
rates and intragenic SMN mutations have to be evaluat-
ed. The SMA carrier frequency in the Korean population
appears to be 1 in 50, which indicates the prevalence of
SMA in Korea is similar to that in the Western countries.
The frequency of individuals with the ‘2+0’genotype was
estimated to be 1.0%. In MLPA analysis for determina-
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Fig. 1. Electrophoreogram of SMN1:
SMN2=1:3. The carrier is heterozygous
for the deletion of the SMN1 gene as
shown by reduction in peak heights
from 2 probes for exons 7 and 8 (clos-
ed arrows). The relative peak height
ratios of SMN2 gene increase to app-
roximately 1.5, indicating the presence
of 3 copies of SMN2 (open arrows).
tion of variations in SMN2 copy numbers, it is important
to use appropriate reference samples with normal copy
numbers. 
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